L Catterton

Kurma Partners is a Paris-based life sciences venture capital firm founded in 2013, focused on seed, Series A, and Series B investments in innovative biopharmaceutical and biotech companies primarily in France and the broader European market, applying deep scientific expertise in drug discovery, clinical development, and therapeutic area strategy. The firm invests with initial checks from $3 million to $15 million in companies developing novel small molecules, biologics, and gene therapy approaches in oncology, immunology, neuroscience, and rare diseases, with particular strength in backing companies spinning out from French and European academic medical centres. Portfolio companies include Abivax, the French biopharmaceutical company listed on Euronext; Dynacure, the Swiss clinical-stage company developing treatments for rare muscle diseases; EnovaPoint, a clinical-stage biotech; and Inotrem, the French company developing treatments for septic shock and inflammatory diseases. Beyond its original investments, the portfolio includes additional European clinical-stage biopharmaceutical companies.